Treatment of Gastric and Gastroesophageal Cancers—Do We Really Need Anthracyclines?
Sign Up to like & getrecommendations! Published in 2017 at "JAMA Oncology"
DOI: 10.1001/jamaoncol.2016.3064
Abstract: Combination chemotherapy has been shown to be superior to single-agent therapy in gastric and gastroesophageal cancers. However, there is no consensus regarding the optimal regimen. Epirubicin-containing regimens are considered standard in parts of Europe, but… read more here.
Keywords: treatment gastric; anthracyclines treatment; gastroesophageal; gastric gastroesophageal ... See more keywords
Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer letters"
DOI: 10.1016/j.canlet.2020.09.014
Abstract: Gastroesophageal cancers (GOCs) represent some of the most common cancers globally and are linked with poor survival rates. The current standard of care includes multimodal chemotherapy, radiotherapy and surgery. However, up to two-thirds of patients… read more here.
Keywords: chemotherapy; immune checkpoint; cooperation chemotherapy; cancer ... See more keywords
Nivolumab with or without chemotherapy for metastatic gastroesophageal cancers and future perspectives
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2139241
Abstract: ABSTRACT Introduction Gastroesophageal cancers (GEC) are frequently found at the advanced stage. GEC treatment advancements have been limited and prognosis, therefore, remains poor. Through numerous clinical trials, the addition of immune checkpoint inhibitors, including nivolumab,… read more here.
Keywords: nivolumab without; gastroesophageal; chemotherapy metastatic; gastroesophageal cancers ... See more keywords
Immune checkpoint inhibitors in resectable gastroesophageal cancers - a review
Sign Up to like & getrecommendations! Published in 2022 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359221139625
Abstract: Gastroesophageal cancers (GEC) have a poor survival rate of 20–30% at 5 years, often due to delayed presentations. Neoadjuvant chemoradiotherapy (CRT) followed by surgery or peri-operative chemotherapy and surgery are widely used as the standard of… read more here.
Keywords: gec; resectable gec; checkpoint inhibitors; immune checkpoint ... See more keywords
Referral-to-treatment attrition and its impact on outcomes of patients with advanced gastroesophageal cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.e16504
Abstract: e16504Background: Advanced gastroesophageal cancers (AGCs) are aggressive tumors. Prior research has demonstrated that patients with poor prognostic cancers are inconsistently or infrequently refer... read more here.
Keywords: impact outcomes; advanced gastroesophageal; attrition impact; referral treatment ... See more keywords
Localized Gastroesophageal Cancers: Can We Shift the Current Treatment Paradigms?
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Comprehensive Cancer Network : JNCCN"
DOI: 10.6004/jnccn.2022.0013
Abstract: Our knowledge of fundamental molecular and immunologic intricacies of gastric and esophageal cancers, although lagging substantially compared to that of other cancers that impose similar health burdens globally, is now on the rise. Because cancers… read more here.
Keywords: cancers shift; shift current; localized gastroesophageal; gastroesophageal cancers ... See more keywords